Please assess the completion status of the following clinical trial:

Trial Title: A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients diagnosed with (primary or secondary) Myelodysplastic Syndrome including chronic myelomonocytic leukemia (CMML) with an International Prognostic Scoring System more than or equal to Interferon-1~* Patients who have never treated with hypomethylating agent (azacitidine and decitabine)~* Female patients who are postmenopausal or received contraceptive operation or refrain from sexual relations.~* Women of childbearing potential should conduct an effective method of birth control as defined in protocol, in case of male patients who will not have a baby within 2 months after the completion of decitabine therapy~Exclusion Criteria:~* Patients diagnosed with acute myelogenous leukemia (bone marrow stem cell counts exceeding 20 %) or other progressive malignant diseases~* Patients with active infection of virus or bacteria~* Patients who used to be treated with azacitidine or decitabine~* Patients who are hypersensitive to excipients of decitabine~* Patients who are pregnant and breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).